Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5803
- TODAY'S CHANGE (%)0.0012 (0.2072%)
- Bid / Lots0.5798/ 1
- Ask / Lots0.5799/ 47
- Open / Previous Close0.5700 / 0.5791
- Day Range
- 52 Week Range
- Volume198,027
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 175 | 0.57 |
| 09:36 ET | 18553 | 0.57 |
| 09:38 ET | 573 | 0.579 |
| 09:41 ET | 3425 | 0.5802 |
| 09:43 ET | 600 | 0.58 |
| 09:48 ET | 200 | 0.5788 |
| 09:52 ET | 400 | 0.5791 |
| 09:54 ET | 2838 | 0.5791 |
| 10:01 ET | 400 | 0.5791 |
| 10:03 ET | 3600 | 0.5791 |
| 10:06 ET | 1487 | 0.5789 |
| 10:08 ET | 600 | 0.5788 |
| 10:10 ET | 783 | 0.5788 |
| 10:14 ET | 300 | 0.5794 |
| 10:15 ET | 100 | 0.5722 |
| 10:19 ET | 100 | 0.5722 |
| 10:26 ET | 100 | 0.5722 |
| 10:28 ET | 4940 | 0.5772 |
| 10:32 ET | 268 | 0.57735 |
| 10:35 ET | 100 | 0.57735 |
| 10:39 ET | 600 | 0.57735 |
| 10:44 ET | 100 | 0.57735 |
| 10:46 ET | 300 | 0.57495 |
| 10:50 ET | 1976 | 0.5748 |
| 10:51 ET | 1687 | 0.57485 |
| 10:53 ET | 400 | 0.5748 |
| 10:55 ET | 300 | 0.5725 |
| 10:57 ET | 1025 | 0.5748 |
| 11:00 ET | 100 | 0.5748 |
| 11:02 ET | 3100 | 0.5771 |
| 11:04 ET | 100 | 0.5748 |
| 11:08 ET | 600 | 0.576 |
| 11:09 ET | 800 | 0.5766 |
| 11:11 ET | 1685 | 0.57945 |
| 11:18 ET | 200 | 0.5802 |
| 11:20 ET | 100 | 0.5807 |
| 11:22 ET | 100 | 0.5807 |
| 11:29 ET | 2384 | 0.5807 |
| 11:31 ET | 100 | 0.5807 |
| 11:36 ET | 100 | 0.5807 |
| 11:40 ET | 100 | 0.5807 |
| 11:42 ET | 100 | 0.5807 |
| 11:45 ET | 408 | 0.5807 |
| 11:49 ET | 100 | 0.5807 |
| 11:51 ET | 100 | 0.5807 |
| 11:54 ET | 978 | 0.5807 |
| 11:56 ET | 100 | 0.5807 |
| 11:58 ET | 864 | 0.5807 |
| 12:00 ET | 100 | 0.5807 |
| 12:02 ET | 100 | 0.5808 |
| 12:07 ET | 599 | 0.5813 |
| 12:09 ET | 416 | 0.5808 |
| 12:12 ET | 100 | 0.5808 |
| 12:14 ET | 100 | 0.5813 |
| 12:16 ET | 400 | 0.5803 |
| 12:20 ET | 703 | 0.5813 |
| 12:21 ET | 2026 | 0.5813 |
| 12:25 ET | 100 | 0.5814 |
| 12:30 ET | 100 | 0.58085 |
| 12:32 ET | 100 | 0.58085 |
| 12:38 ET | 100 | 0.58085 |
| 12:39 ET | 100 | 0.58085 |
| 12:41 ET | 100 | 0.5809 |
| 12:43 ET | 100 | 0.5809 |
| 12:45 ET | 300 | 0.5804 |
| 12:50 ET | 100 | 0.5809 |
| 12:52 ET | 100 | 0.5809 |
| 01:01 ET | 100 | 0.58085 |
| 01:03 ET | 306 | 0.58085 |
| 01:06 ET | 6161 | 0.5802 |
| 01:08 ET | 391 | 0.58035 |
| 01:10 ET | 100 | 0.58035 |
| 01:14 ET | 100 | 0.58035 |
| 01:15 ET | 100 | 0.58035 |
| 01:17 ET | 3256 | 0.5803 |
| 01:26 ET | 100 | 0.5803 |
| 01:28 ET | 5869 | 0.5802 |
| 01:33 ET | 213 | 0.58 |
| 01:35 ET | 6635 | 0.5803 |
| 01:39 ET | 526 | 0.5802 |
| 01:44 ET | 100 | 0.5802 |
| 01:48 ET | 2566 | 0.5802 |
| 01:53 ET | 3056 | 0.5802 |
| 01:55 ET | 100 | 0.58 |
| 01:57 ET | 500 | 0.58 |
| 02:02 ET | 666 | 0.5801 |
| 02:04 ET | 2035 | 0.5801 |
| 02:06 ET | 11533 | 0.5802 |
| 02:09 ET | 896 | 0.5802 |
| 02:11 ET | 425 | 0.5802 |
| 02:13 ET | 100 | 0.58025 |
| 02:15 ET | 1100 | 0.5802 |
| 02:18 ET | 400 | 0.58 |
| 02:20 ET | 407 | 0.5801 |
| 02:22 ET | 600 | 0.5801 |
| 02:24 ET | 100 | 0.58 |
| 02:27 ET | 261 | 0.5801 |
| 02:31 ET | 211 | 0.58 |
| 02:36 ET | 200 | 0.58005 |
| 02:40 ET | 400 | 0.58 |
| 02:44 ET | 200 | 0.58 |
| 02:47 ET | 1431 | 0.58 |
| 02:51 ET | 200 | 0.58 |
| 02:54 ET | 2087 | 0.58 |
| 02:56 ET | 300 | 0.58 |
| 03:03 ET | 100 | 0.58 |
| 03:05 ET | 300 | 0.58 |
| 03:07 ET | 100 | 0.58 |
| 03:09 ET | 100 | 0.58 |
| 03:12 ET | 397 | 0.58 |
| 03:14 ET | 483 | 0.58 |
| 03:16 ET | 377 | 0.5801 |
| 03:18 ET | 100 | 0.58 |
| 03:20 ET | 100 | 0.58 |
| 03:23 ET | 100 | 0.58 |
| 03:25 ET | 100 | 0.58 |
| 03:30 ET | 100 | 0.58 |
| 03:32 ET | 200 | 0.58 |
| 03:36 ET | 4421 | 0.5808 |
| 03:38 ET | 16306 | 0.5828 |
| 03:39 ET | 5897 | 0.583 |
| 03:45 ET | 700 | 0.5829 |
| 03:48 ET | 1543 | 0.583 |
| 03:50 ET | 2379 | 0.583 |
| 03:54 ET | 1230 | 0.5829 |
| 03:56 ET | 1110 | 0.5829 |
| 03:57 ET | 691 | 0.5829 |
| 03:59 ET | 14888 | 0.5803 |
Jun 7, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), from 5:59PM ET on Friday Jun 07, 2024 by Dow Jones
5:59PM ET on Friday Jun 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 42.2M | -0.4x | --- |
LAVA Therapeutics NV | 47.3M | -1.8x | --- |
DURECT Corp | 39.7M | -1.5x | --- |
Atara Biotherapeutics Inc | 37.8M | -0.2x | --- |
Cue Biopharma Inc | 47.7M | -0.9x | --- |
Evogene Ltd | 32.6M | -1.4x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Chief Executive Officer, Director
- Christopher Kirk
- Chief Financial Officer, Secretary
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.2M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.28 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
